Orchard Therapeutics (ORTX) Short Interest Ratio & Short Volume

Short interest is the volume of Orchard Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 15th, investors have sold 31,500 shares of ORTX short. 0.14% of Orchard Therapeutics' shares are currently sold short. Learn More on Orchard Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.14% of Orchard Therapeutics' floating shares are currently sold short.

Orchard Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 31,500 shares, an increase of 15.8% from the previous total of 27,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Orchard Therapeutics currently has issued a total of 22,760,000 shares. Some of Orchard Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Orchard Therapeutics currently has a public float of 22,370,000 shares.

0.14% of Orchard Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Orchard Therapeutics: NGM Biopharmaceuticals, Inc. (4.52%), Kinnate Biopharma Inc. (2.01%), PepGen Inc. (1.25%), Pulse Biosciences, Inc. (17.96%), Revance Therapeutics, Inc. (11.16%), Anika Therapeutics, Inc. (5.73%), Surmodics, Inc. (3.47%), Adaptive Biotechnologies Co. (7.23%), Nkarta, Inc. (11.27%), Tourmaline Bio, Inc. (11.58%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.10 billion), General Motors ($3.90 billion), Charter Communications, Inc. ($3.31 billion), Occidental Petroleum Co. ($2.91 billion), Tractor Supply ($2.75 billion), Moderna, Inc. ($2.44 billion), Coinbase Global, Inc. ($2.10 billion), United Rentals, Inc. ($2.09 billion), Royal Caribbean Cruises Ltd. ($2.03 billion), and Rivian Automotive, Inc. ($1.89 billion). View all of the most shorted stocks.

Short selling ORTX is an investing strategy that aims to generate trading profit from Orchard Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Orchard Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ORTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORTX, twice per month. The most recent reporting period available is January, 15 2024.